Compare MTZ & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | UTHR |
|---|---|---|
| Founded | 1929 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | MTZ | UTHR |
|---|---|---|
| Price | $219.26 | $489.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | $228.89 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 753.0K | 424.3K |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.77 | 16.08 |
| EPS | 4.20 | ★ 26.38 |
| Revenue | ★ $13,762,473,000.00 | $3,128,400,000.00 |
| Revenue This Year | $15.48 | $13.64 |
| Revenue Next Year | $10.21 | $5.78 |
| P/E Ratio | $52.30 | ★ $18.55 |
| Revenue Growth | 12.99 | ★ 13.50 |
| 52 Week Low | $99.70 | $266.98 |
| 52 Week High | $224.03 | $492.62 |
| Indicator | MTZ | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 68.10 |
| Support Level | $207.94 | $470.13 |
| Resistance Level | $214.00 | $492.62 |
| Average True Range (ATR) | 8.12 | 10.72 |
| MACD | 2.47 | -0.53 |
| Stochastic Oscillator | 90.92 | 89.55 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.